Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors
Suarez-Almazor, M. E. Pundole, X. Abdel-Wahab, N. Johnson, D. B. Gupta, D. Glezerman, I. Cooksley, Timothy J Anderson, R. Blidner, A. Choi, J.
Suarez-Almazor, M. E.
Pundole, X.
Abdel-Wahab, N.
Johnson, D. B.
Gupta, D.
Glezerman, I.
Cooksley, Timothy J
Anderson, R.
Blidner, A.
Choi, J.
Citations
Altmetric:
Abstract
Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.
Keywords: Arthralgia; Arthritis; Cardiomyopathy; Corticosteroids; Immunomodulation agents; Myocarditis; Myositis; Other immunosuppressive agents; Polymyalgia.
Description
Date
2020
Publisher
Collections
Keywords
Type
Article
Citation
Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020.